Wealthfront Advisers
CRL icon

Wealthfront Advisers’s Charles River Laboratories CRL Stock Holding History

Wealthfront Advisers’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Buy
1,720
+111
+7% +$19.8K ﹤0.01% 931
2026
Q1 		$278K Buy
1,609
+243
+18% +$45.1K ﹤0.01% 956
2025
Q4 		$272K Buy
+1,366
New +$248K ﹤0.01% 948
2025
Q1 		– Sell
-4,567
Closed -$843K – 937
2024
Q4 		$843K Sell
4,567
-3,613
-44% -$696K ﹤0.01% 696
2024
Q3 		$1.61M Sell
8,180
-621
-7% -$129K 0.01% 545
2024
Q2 		$1.82M Sell
8,801
-407
-4% -$92.2K 0.01% 509
2024
Q1 		$2.49M Sell
9,208
-252
-3% -$60.2K 0.01% 434
2023
Q4 		$2.24M Buy
9,460
+8,081
+586% +$1.59M 0.01% 436
2023
Q3 		$270K Buy
1,379
+205
+17% +$42.1K ﹤0.01% 774
2023
Q2 		$247K Sell
1,174
-629
-35% -$125K ﹤0.01% 792
2023
Q1 		$364K Sell
1,803
-331
-16% -$75K ﹤0.01% 721
2022
Q4 		$465K Buy
2,134
+285
+15% +$62.2K ﹤0.01% 644
2022
Q3 		$364K Buy
1,849
+464
+34% +$100K ﹤0.01% 660
2022
Q2 		$296K Buy
1,385
+333
+32% +$81.4K ﹤0.01% 687
2022
Q1 		$298K Sell
1,052
-4,157
-80% -$1.28M ﹤0.01% 707
2021
Q4 		$1.96M Buy
5,209
+2,085
+67% +$810K 0.01% 393
2021
Q3 		$1.29M Buy
3,124
+2,115
+210% +$878K 0.01% 434
2021
Q2 		$373K Buy
1,009
+162
+19% +$54.1K ﹤0.01% 554
2021
Q1 		$245K Buy
+847
New +$235K ﹤0.01% 523

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return

Wealthfront Advisers's CRL Position: Q2 2026 in Review

Wealthfront Advisers increased its Charles River Laboratories (CRL) stake by 6.9% in Q2 2026, buying an estimated $19.8K and bringing the position to 1,720 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #931.

Wealthfront Advisers first reported a position in CRL in Q1 2021 and has held it in 19 quarters since. The position peaked at $2.49M in Q1 2024. 366 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Wealthfront Advisers held 1,720 shares of Charles River Laboratories worth $390K as of Q2 2026.
  • Wealthfront Advisers bought 111 Charles River Laboratories shares in Q2 2026, an estimated $19.8K.
  • Charles River Laboratories made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #931 holding.
  • Wealthfront Advisers first reported a position in Charles River Laboratories in Q1 2021 and has held it in 19 quarters since.
  • Wealthfront Advisers's Charles River Laboratories position peaked at $2.49M in Q1 2024.
  • 366 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.